Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
132.89
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glaukos Corp
< Previous
1
2
3
Next >
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
February 27, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Citi Healthcare Conference
February 15, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
February 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 28, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Stephens Annual Investment Conference
November 07, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
October 12, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
September 28, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
September 07, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
September 06, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
August 24, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
August 03, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces Second Quarter 2022 Financial Results
August 03, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
July 13, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the William Blair Growth Stock Conference
June 02, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
May 20, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces First Quarter 2022 Financial Results
May 04, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 21, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2021 Sustainability Report
April 20, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
April 13, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
March 14, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Executive Leadership Changes
February 07, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
February 01, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.